ライフサイエンスコーパス: rationale for

1 In this article, we describe the molecular rationale for 5 distinct approaches to inhibiting polyme

2 ves resistance to ibrutinib and provides the rationale for a combination strategy that includes ibrut

3 This highly powered study provides strong rationale for a confirmatory phase III clinical trial.

4 he MYC G-quadruplex and i-motif, providing a rationale for a molecular switch mechanism driven by SP1

5 This rapidly changing scenario provides a rationale for a more systematic collection of patient-re

6 These data provide a rationale for a new pharmacologic therapy for obstructiv

7 ent on mitochondrial metabolism, providing a rationale for a new therapeutic approach.

8 Our data provides a rationale for a novel anti-fibrotic strategy specificall

9 in alcohol-seeking and relapse and present a rationale for a novel pharmacological intervention that

10 a broad spectrum of data, constitutes a neat rationale for a numerically effective and theoretically

11 In total, our results undermine the rationale for a series of current clinical trials and pr

12 ve metastasis, and provide a mechanism-based rationale for a stroma-directed therapy for PDAC.

13 blocks metastatic spread, thus providing the rationale for a therapeutic strategy based on PIN1 inhib

14 In this article, we give the rationale for a therapeutic transcatheter interatrial sh

15 After defining the gap between a good rationale for a tracer and implementation in the clinica

16 The first structural rationale for acetone carboxylation is presented here, f

17 e antitumor immunity, as well as support the rationale for administering immunotherapy in early-stage

18 ompared with other populations, suggesting a rationale for admixture mapping.

19 This finding provides a rationale for an entirely new class of analgesics by inh

20 stable 2HB state and offers a tension-based rationale for an optimal NL length to ensure processivit

21 ly used survivorship programmes, discuss the rationale for and potential benefits of expanded types o

22 ere provide the pre-clinical and mechanistic rationale for assessing ARID1A defects as a biomarker of

23 The rationale for bariatric surgery reducing CVD events is d

24 hould be included based on strong scientific rationale for benefit.

25 Together, these studies provide a rationale for BET inhibition in TNBC and present mechani

26 B cell lymphomagenesis and provides a strong rationale for blocking the IL-6 pathway in patients with

27 We outline biophysical and evolutionary rationale for broad variation in protein family sizes, p

28 ctivity in our omega-3 metabolic engineering rationales for Camelina.

29 he core pharmacophore for MC4R and provide a rationale for careful assay selection for agonist screen

30 The results provide a rationale for categorizing fluid-feeding insects into tw

31 fined, followed by sections on epidemiology, rationale for changes from prior criteria, clinical eval

32 y associated with poor outcomes, providing a rationale for chromosomal loss patterns in neuroblastoma

33 Furthermore, these results support a rationale for chronic inflammation as a potential modifi

34 TTEs as well as the appropriate use criteria rationale for classifying studies as rarely appropriate.

35 ibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivat

36 Our findings provide the rationale for clinical observations that relate atopy wi

37 EAC in a preclinical model, establishing the rationale for clinical testing.

38 Our findings provide a rationale for clinical trials testing Akt and EGFR inhib

39 across multiple species and provide a clear rationale for clinical trials with this compound.

40 These results provide a strong rationale for co-targeting AR bypass pathways with initi

41 These features provide a strong rationale for combination immunotherapy approaches with

42 ficance: These results provide a mechanistic rationale for combination therapy of CXCR4 and BCL-2 inh

43 These data provide a rationale for combination therapy of Fc-engineered antib

44 fects on cell growth inhibition, providing a rationale for combination therapy with inhibitors of the

45 Furthermore, our results provide a strong rationale for combination treatment strategies targeting

46 tance mechanism to gemcitabine and provide a rationale for combining chemo/radiotherapy with TIMP1 in

47 Thus, these results may provide a rationale for combining PARP and EZH2 inhibition as a th

48 Our rationale for combining these seemingly disparate techni

49 intratumoral T cell infiltration, provide a rationale for combining these targeted therapies with im

50 Our data provide rationale for combining vascular endothelial growth fact

51 Our work provides a rationale for continued development of a structural fram

52 Investigators rarely presented their rationale for control selection (n = 25/134; 18.7%); how

53 s in the context of cells, which provide the rationale for designing approaches to control the assemb

54 These results offer a mechanistic rationale for designing membrane-selective and sequence-

55 ase function and regulation has provided the rationale for developing E3-targeting therapeutics for t

56 ntial to prevent these sequelae, providing a rationale for developing strategies aimed at acceleratin

57 The data provide rationale for developing TCRm antibodies as therapeutic

58 Moreover, our work also provides a rationale for development of CXCR2 antagonists to inhibi

59 in acute leukaemia and suggest a mechanistic rationale for disrupting the YEATS domain in disease.

60 the basis for substrate specificity, or the rationale for donor specificity for any LuxI member.

61 ha in inflammatory atherogenesis and provide rationale for dual cytokine antagonism in future studies

62 The details regarding the evidence and rationale for each recommendation are presented in the A

63 cation of epigenetic regulators, providing a rationale for epigenetic therapy in ER-positive breast c

64 helping nutrition researchers to clarify the rationale for examining mediation, avoid common pitfalls

65 Rationale for excluding patients should be clearly artic

66 outcomes should be included absent specific rationale for exclusion.

67 n this Personal View, we explain further the rationale for expanding the genetic database of NIRVs an

68 Our findings provide strong rationale for exploration of systemic metabolism as a th

69 iral production during ART, thus providing a rationale for exploring immunotherapeutic approaches in

70 additional evidence has emerged to suggest a rationale for extending statin consideration to an even

71 is of ER-positive breast cancer and provides rationale for FDA-approved use of mTORC1 inhibitors in c

72 tion from ADP to rigor provides a structural rationale for force sensitivity in this step of the mech

73 These data provide a strong rationale for further development of the BeGEV regimen.

74 These data provide a strong rationale for further development of this approach, alon

75 These results provide a strong rationale for further exploration of anti-IL-1 strategie

76 ption for locally advanced cSCC and provides rationale for further investigation in future clinical t

77 elated pleural fibrosis and provide a strong rationale for further investigation of GSK-3beta signali

78 This broad review provides rationale for further investigation of multimodality the

79 Our results provide a rationale for further investigation on the therapeutic p

80 The AIO-FLOT3 trial provides a rationale for further randomized clinical trials.

81 ve or treatment-resistant NSCLC, providing a rationale for further studies of avelumab in this diseas

82 traperitoneal seeding of EOC and provide the rationale for future studies targeting Ncad in preclinic

83 troke or transient ischemic attack provide a rationale for future trials of improved thrombus aspirat

84 These findings provide a rationale for genetic modification of stem cells and con

85 Guidelines and the rationale for grading the strength of each recommendatio

86 life-threatening infections provides a clear rationale for hematopoetic stem cell transplantation (HS

87 GR genomic binding and provide a biophysical rationale for how promiscuous binding by GR allows funct

88 TP-hydrolysis mechanism, provide a molecular rationale for how the Rho ATPase domains distinguishes b

89 To investigate additional rationale for human telomerase assembly as H/ACA RNP, we

90 pendent of BCR-ABL for survival, providing a rationale for identifying and targeting kinase-independe

91 In summary, our work offers a mechanistic rationale for IDH1 inhibition as a metabolic strategy to

92 e I IFN in skin fibrosis, and they provide a rationale for IFNAR1 inhibition in scleroderma.

93 y homogeneous phenotype of LTBI, providing a rationale for immunological risk stratification to impro

94 These results provide a rationale for improving anti-EGFR therapeutic efficacy t

95 ollectively, the data call into question the rationale for increasingly widespread self-medication wi

96 essor of metastasis and provide a compelling rationale for inhibition of ECT2 as a therapeutic approa

97 terminant of TNBC aggressiveness and provide rationale for investigating age-stratified therapies des

98 These findings support the rationale for investigating early intervention with a KM

99 ing LCFA metabolism and therefore provides a rationale for investigating its role in LCFA-utilizing p

100 These results provide a rationale for investigating the efficacy of combining se

101 tor in their genome sequences, providing the rationale for investigating these receptors to understan

102 Our findings provide a strong rationale for investigation of the use of TKIs in combin

103 vides the basis to evaluate a new biological rationale for its activity when used clinically to initi

104 tive effects during inflammation; however, a rationale for its apical expression has been lacking.

105 initiation involving IMP3 and they provide a rationale for its association with aggressive disease an

106 agonalized with long Ni-C bonds, providing a rationale for its current synthetic inaccessibility.

107 d stoichiometry for A116V moPrP, providing a rationale for its increased channel-forming capability.

108 ubset, and provide a systems-based molecular rationale for its key functions downstream of IL-15.

109 survival of mature T cells, which provides a rationale for its potential use as an immunotherapeutic

110 tagenic deaminase, human AID, and provides a rationale for its regulation.

111 ng drives CRPC, and they offer a mechanistic rationale for its therapeutic targeting in this disease.

112 ctrum therapeutic use of GC, the biochemical rationale for locally treating inflammatory skin conditi

113 These data provide the fundamental basis and rationale for management of the axilla in clinical trial

114 Following a discussion of the rationale for measuring costs, this review contextualize

115 rate in myeloid transformation and provide a rationale for mechanism-based therapy in CMML patients w

116 mbursement pending demonstration of clinical rationale for Medicaid patients with inappropriate PCIs.

117 Our results demonstrate the rationale for MHC-matching in neural cell grafting to th

118 s of molecular data were combined, providing rationale for microsatellite instability for 8 of the 9

119 re-test survey that ascertained the clinical rationale for MR imaging, the clinical management plan i

120 Here we provide a first rationale for N184K pathogenicity.

121 increase tumour immunogenicity and provide a rationale for new combination regimens comprising CDK4/6

122 g, we describe how we practice and provide a rationale for our approach.

123 e features of available RCTs and provide the rationale for our recommendations.

124 y of early HCV infection, and the scientific rationale for PEP.

125 in exocrine gland development and support a rationale for performing exocrine functional tests for p

126 Our findings provide a novel rationale for personalized and genome-informed disease p

127 e neuromodulatory dysregulation provides the rationale for pharmacological interventions.

128 Our results suggest a rationale for phlebovirus entry in late endosomes.

129 To determine TrkA expression in MCC as a rationale for potential targeted therapy.

130 m of breast cancer metastasis and provides a rationale for potential therapeutic interventions in the

131 ls of decision making could provide a strong rationale for precommitment strategies and that interdis

132 kinetics of Lyp1 and provide a mechanism and rationale for previous observations.

133 These data provide a strong rationale for prospective trials with DAAs in this setti

134 argets both the liver and the eye provides a rationale for protecting the severely premature infant f

135 The proposed regulatory strategy suggests a rationale for quorum-sensing-dependent stimulation of th

136 The panel formulated and provided the rationale for recommendations on selected ventilatory in

137 This study provides additional rationale for scaling up violence prevention interventio

138 The report describes the consensus process, rationale for selecting data elements to be reported, de

139 Here we describe and apply a novel rationale for size-normalizing the mass of the calcite p

140 The rationale for soil-transmitted helminthiasis (STH)- and

141 e numerous coordination complexes provides a rationale for some of the spectacular contributions that

142 ly dangerous plaques and offer a mechanistic rationale for SPM therapy to promote plaque stability.

143 nalyses provide an intuitive and mechanistic rationale for strategic delay, which contrasts with the

144 Finally, we provide a rationale for stratification of human patients with lung

145 ics: pathophysiology, clinical presentation, rationale for stratification, imaging, massive PE manage

146 nic groups in Africa and Europe, providing a rationale for such independent genomic datasets.

147 This review outlines the rationale for surgical chromophore application, the weak

148 basis for the TNM staging system and is the rationale for surgical resection of tumor-draining lymph

149 or influenza vaccine responses and provide a rationale for targeted, ex vivo Ag-driven molecular prof

150 Overall, our preclinical data provide the rationale for targeting DUB enzyme Rpn11 upstream of 20S

151 YC in malignant transformation and provide a rationale for targeting EBV's roles in cell cycle modula

152 ared with ovarian primary cells, providing a rationale for targeting HuR.

153 oxylmethylation on RAB GTPases and provide a rationale for targeting ICMT in the treatment of metasta

154 This regulatory loop provides a mechanistic rationale for targeting ILK to suppress oncogenic KRAS s

155 These findings provide a rationale for targeting MAOA and its associated molecule

156 Our results support the rationale for targeting metabolism in sepsis with recomb

157 s HNSCC invasion and metastasis, providing a rationale for targeting PI3K/PDK1 and TGFbeta signaling

158 This provides a rationale for targeting PRMT5 in TMPRSS2:ERG positive pr

159 Our findings provide rationale for targeting signaling via MET and CD44 durin

160 naling axis in tumorigenesis, and provides a rationale for targeting Snail to improve mTOR-targeted t

161 These data provide rationale for targeting specific components of mTORC pat

162 Our results support the rationale for targeting synaptic and extrasynaptic GABAA

163 In addition, this report provides a rationale for targeting the IL-23-TH17-pathway as a trea

164 In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provid

165 ne responses in different cell types and the rationale for targeting Tim-3 for effective cancer immun

166 role in KRAS-driven resistance and provide a rationale for targeting translation to overcome resistan

167 aken together, our findings provide a strong rationale for testing combinations of panPI3K, PI3Kbeta

168 ety profile, our results will provide with a rationale for testing NSAIDs as potential chemoadjuvants

169 Our findings provide a rationale for testing VCAN proteolysis as a predictive a

170 e a foundation for preclinical studies and a rationale for testing whether NMDAR antagonists might be

171 ridoxal 5'-phosphate cofactor and provides a rationale for the allosteric activator function of FXN i

172 Together the data provides a rationale for the bi-partite nature of the ICP4 DNA reco

173 ormally fleeting in hydroxylases, provides a rationale for the carbon-carbon scission reaction cataly

174 more easily than C=O bonds thus providing a rationale for the catalytic observations.

175 results establish a preclinical mechanistic rationale for the clinical development of Axl inhibitors

176 results establish a preclinical mechanistic rationale for the clinical development of AXL inhibitors

177 Overall, our findings provide a preclinical rationale for the clinical development of MALT1 inhibito

178 Our findings provide a rationale for the clinical evaluation of CFI-402257 in p

179 K4 as an oncogene in myeloma and provide the rationale for the clinical evaluation of PAK4 modulator

180 trate for USP6, and they offer a mechanistic rationale for the clinical investigation of Jak and STAT

181 These findings may support the rationale for the clinical testing of peripherally restr

182 ation and inhibition, our study delivers the rationale for the clinically observed phenomenon of resi

183 erent immune checkpoint modulators, form the rationale for the design of immune checkpoint-based immu

184 nigmatic phenomenon of protean agonism and a rationale for the design of such compounds for a G prote

185 ple levels in prostate cancer and provides a rationale for the design of therapies that restore NK ce

186 de a novel drug target that may serve as the rationale for the development of a new therapeutic appro

187 into the role of IL1RAP in CML and a strong rationale for the development of an IL1RAP antibody ther

188 ll carcinoma (RCC), providing a pre-clinical rationale for the development of Axl and Met inhibitors

189 T cell leukemia, establish a mechanism-based rationale for the development of BET bromodomain degrada

190 ral ventromedial medulla provides additional rationale for the development of CB2 receptor-selective

191 popolysaccharides (LPS) interactions provide rationale for the development of non-cytotoxic antibioti

192 totic APC/C by phosphorylation and provide a rationale for the development of selective inhibitors of

193 perties of proNGF and NGF and help provide a rationale for the diverse biological effects of NGF and

194 arding Abeta oligomers, and provide a strong rationale for the evaluation of crenezumab as a potentia

195 mented safety profile of this drug provide a rationale for the evaluation of niclosamide in the manag

196 These findings also serve to provide a rationale for the evolution of the BCO-related outlier R

197 source of diverse magnetic phenomena, and a rationale for the existence of intermetallics with giant

198 Our data provide a rationale for the exploitation of immunotherapeutic appr

199 preclinical proof of concept and mechanistic rationale for the exploration of SSTNIGF1R as an experim

200 It provides a rationale for the exploration of the CYGB pathway as a m

201 This provides a molecular-level rationale for the exposure of the hydrophobic fusion loo

202 We review the rationale for the guideline recommendations, principles

203 pha PtdIns/PtdCho exchange cycle and offer a rationale for the high conservation of particular sets o

204 However, the rationale for the high-temperature stability of precipit

205 beta interaction results suggest a molecular rationale for the higher AD prevalence among smokers, an

206 ng the nuclear export sequence), providing a rationale for the increased cytoplasmic aggregation of R

207 This surprising result provides a rationale for the lack of success in synthesizing the he

208 A rationale for the mechanochemical effect on this photois

209 al studies on SGLT2 inhibitors and provide a rationale for the mode of action of these drugs.

210 ructure in the protein provides a structural rationale for the observation that unfolding is hierarch

211 A mechanistic rationale for the observed chemoselectivity is provided.

212 he binding site, thus providing a structural rationale for the observed disruption of the transition

213 ts, supported by DFT calculations, suggest a rationale for the observed photophysical properties that

214 An orbital-based rationale for the observed results is presented.

215 hts into enzyme-inhibitor interactions and a rationale for the observed selectivity and potency.

216 We provide here a molecular rationale for the observed spectral properties of Sander

217 Herein, we describe the rationale for the Oral Iron Repletion effects on Oxygen

218 us anaplastic T-cell lymphoma, and provide a rationale for the pharmacologic inhibition of EZH2 activ

219 reasons why this project was initiated, the rationale for the planned work, and the expected benefit

220 This unveils a molecular rationale for the pleiotropic role of the protein qualit

221 structure and spectroscopic investigations a rationale for the positive impact of acetonitrile is pro

222 mplexed with some of the compounds provide a rationale for the potency and specificity.

223 Our data provide a mechanistic rationale for the powerful ability of BAP1 to regulate g

224 The rationale for the present study was that a mechanical ap

225 which phages circumvent them, and provide a rationale for the prevalence of pilus glycosylation in n

226 is, Leu, and Asp, respectively), providing a rationale for the purine base specificity of S. venezuel

227 These results provide the first rationale for the reduced synaptic spine localization of

228 uring information transmission, suggesting a rationale for the regulation of these information proces

229 proposal is intriguing, as it offers both a rationale for the relatively high hydrogen-atom-transfer

230 DNA-binding domain and provide a biophysical rationale for the reported functional regulation of the

231 Our results suggest a rationale for the responsiveness of depression in some p

232 ansporter NRAMP1 to the vacuole, providing a rationale for the reversion of nramp3nramp4 phenotypes.

233 ism of AEP and DOT1L and suggest a molecular rationale for the simultaneous inhibition of the MLL fus

234 lasma membrane versus endosomes, providing a rationale for the spatial encoding of cAMP signaling.

235 A theoretical rationale for the specific experimental conditions to be

236 ther, this structural information provides a rationale for the stimulation of MalK ATPase activity by

237 Our results provide rationale for the targeting of amyloid-beta and lacunes

238 Overall, these results provide a rationale for the therapeutic targeting of METTL3 in mye

239 gnalling pathway, thereby providing a simple rationale for the upregulation of ARHGAP36 in medullobla

240 Further, they offer a preclinical rationale for the use of ADCC-optimized antibodies to tr

241 ase revascularization exist, and much of the rationale for the use of antiplatelet agents after endov

242 Specifically, we provide a molecular rationale for the use of BET inhibitors to treat patient

243 Finally, our results provide a rationale for the use of combination therapy, tailored o

244 ic BCR signaling, thus providing a molecular rationale for the use of HSP90 inhibitors in the treatme

245 olangiocarcinoma and establish a mechanistic rationale for the use of low-dose paclitaxel in blocking

246 together, our results provide a preclinical rationale for the use of NR4A1 small-molecule antagonist

247 ur results offered a preclinical mechanistic rationale for the use of PARP and ATR inhibitors to impr

248 The authors posit a rationale for the use of PCSK9 antibodies in patients wi

249 Overall, our data provide a rationale for the use of PD-1-selected TILs in ACT.

250 ess, the efficacy of buparlisib supports the rationale for the use of PI3K inhibitors plus endocrine

251 s and the clinical evidence that support the rationale for the use of SGLT2 inhibitors in patients wi

252 Therefore, the scientific rationale for the use of tolerogenic DC therapy in the f

253 ation of inflammatory response and provide a rationale for the use of Wnt11 to manipulate human disea

254 These findings may inform future rationales for the development of iNKT-based therapies a

255 d DNaseI hypersensitivity sites, providing a rationale for their effects.

256 Uch37 in cell cycle progression, providing a rationale for their function in cellular proliferation a

257 sual structure of these complexes provides a rationale for their unexpected reactivity.

258 eemingly clear mechanism of action and solid rationale for their use in cancer therapy, mTORis have m

259 Furthermore, they provide biologic rationale for therapeutic strategies in AML targeting th

260 hat promotes OSC tumor growth, and provide a rationale for therapeutic targeting of this pathway for

261 These data provide a rationale for therapeutic TRIM24 targeting in SPOP mutan

262 These data provide the rationale for therapeutic use of avelumab in metastatic

263 and FTD by acting on autophagy, providing a rationale for therapeutic use of DBS and synaptic stimul

264 n and to foster exercise tolerance provide a rationale for therapeutic use of IL-37 in the treatment

265 Our finding provides a rationale for therapeutically enhancing VISTA-mediated p

266 this cancer-relevant function has provided a rationale for therapeutically targeting proteostasis reg

267 uitin ligase activity; however, a structural rationale for these observations is not clear.

268 To provide a molecular rationale for these observations, we study the Dbl-homol

269 earrangements (all pericyclic), and detailed rationales for these latest results are provided.

270 The rationale for this approach is based on modulating the p

271 roscopy, and theory to provide a mechanistic rationale for this process.

272 A mechanistic rationale for this reaction is supported by DFT calculat

273 The rationale for this study was to evaluate the feasibility

274 insights into the reaction mechanism and the rationale for this unusual chemoselectivity.

275 In this paper, we review the rationale for tOPV disposal and describe the global guid

276 of pancreatic beta-cells and underscore the rationale for transient beta-cell rest as a treatment st

277 They provide a rationale for treating PCa with inhibitors of FGF signal

278 slation-related pathways offer a mechanistic rationale for treatment of osteosarcomas and other cance

279 iolet-radiation-induced mutations, providing rationale for treatment with immunotherapy antibodies th

280 Our data provide a rationale for trials of host-directed therapies in TBDM,

281 RATIONALE: For unclear reasons, obese children with asth

282 Our data provide a structural rationale for understanding the phenotypes of temperatur

283 Specifically, we discuss the rationale for upcoming studies, and how novel therapies

284 IFNAR1 suppressed tumor growth providing the rationale for upregulating IFNAR1 to improve anti-cancer

285 Information was sought on study design, rationale for using deceased controls, application of th

286 s and neuronal activity remains unclear, the rationale for using diffusion MRI to monitor neuronal ac

287 The rationale for using HDC/ASCT in PCNSL patients is based

288 file as an antibiotic, our results provide a rationale for using minocycline as a therapeutic agent f

289 Most authors described their rationale for using mixed methods as complementarity and

290 This article describes the rationale for using modeling, an approach to selecting t

291 n of anticipated benefits and the underlying rationale for using monitoring technologies.

292 Our findings provide further support to the rationale for using n-3 PUFAs as a treatment option for

293 Our rationale for using scrambled images is that they contai

294 injection, our findings provide a promising rationale for validation of (18)F-DCFPyL in future prosp

295 perimental analysis provided evidence on the rationale for WaaA regulation.

296 city of the Amy13K CBMs provides a molecular rationale for why E. rectale is able to only use certain

297 ly tested for binding to PDEdelta provides a rationale for why some prenylated proteins, such as KRAS

298 interest in anti-TH2 biologics, we propose a rationale for why they are particularly successful in co

299 ommunication by the Rag GTPases, providing a rationale for why they exist as a dimer and revealing a

300 f adaptive deep brain stimulation provides a rationale for why this approach could be more efficaciou